Burning Rock Biotech (NASDAQ:BNR) Releases Earnings Results, Beats Estimates By $2.04 EPS

Burning Rock Biotech (NASDAQ:BNR) released its quarterly earnings results on Tuesday. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.04, FiscalAI reports. Burning Rock Biotech had a negative return on equity of 9.98% and a negative net margin of 10.27%.The business had revenue of $15.66 million during the quarter, compared to analyst estimates of $19.21 million.

Burning Rock Biotech Price Performance

Shares of Burning Rock Biotech stock opened at $9.07 on Tuesday. The firm has a market cap of $95.42 million, a price-to-earnings ratio of -11.48 and a beta of 1.33. Burning Rock Biotech has a 52-week low of $2.95 and a 52-week high of $41.72. The stock has a 50-day simple moving average of $16.06 and a 200-day simple moving average of $21.35.

Insider Activity

In related news, Director Yusheng Han acquired 314,870 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The shares were acquired at an average cost of $17.36 per share, with a total value of $5,466,143.20. Following the purchase, the director owned 17,672,676 shares of the company’s stock, valued at approximately $306,797,655.36. The trade was a 1.81% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 30.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Burning Rock Biotech stock. Marshall Wace LLP purchased a new position in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned 0.10% of Burning Rock Biotech as of its most recent SEC filing. 30.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.